Published in:
01-02-2014 | Topic paper
Are bisphosphonates an indispensable tool in the era of targeted therapy for renal cell carcinoma and bone metastases?
Authors:
Daniel Keizman, Maya Ish-Shalom, Natalie Maimon, Maya Gottfried
Published in:
World Journal of Urology
|
Issue 1/2014
Login to get access
Abstract
One third of patients with metastatic renal cell carcinoma (RCC) suffer from bone metastases. Skeletal involvement in RCC is associated with the occurrence of skeletal-related events, and may negatively impact on the outcome of patients treated with systemic therapies. In patients with RCC and bone metastases, therapies that inhibit osteoclasts, as bisphosphonates and denosumab, are used as adjunct to systemic targeted therapies to prevent skeletal-related events. Data suggest that they may also improve the outcome of systemic targeted therapies. Herein we review the preclinical and clinical data on their use, as well as remaining open questions.